ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 422

Antibodies to Citrulline From Rheumatoid Arthritis Patients Also Bind Homocitrulline

Mathias Scinocca1, Radha Joseph2, David A. Bell3, Ewa Cairns3 and Lillian J. Barra3, 1Microbiology and Immunology, Schulich School of Medicine and Dentistry, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada, 2Microbiology and Immunology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada, 3Medicine, Division of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: anti-citrullinated protein/peptide antibodies (ACPA), citrulline and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Human Etiology and Pathogenisis

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Antibodies to citrullinated proteins/peptides (ACPA) are specific for Rheumatoid Arthritis (RA). One of ACPA’s targets is citrullinated fibrinogen (citfib) and it is found in inflamed synovium.  Recently, it has been reported that antibodies to homocitrullinated proteins/peptides (AHPA) also occur in RA. Citrulline and homocitrulline are structurally similar. Both can be generated during inflammation, but by different processes. ACPA from RA patients, including those targeting citfib, are arthritogenic.  However, the role of AHPA in RA is not known.  The purpose of this study was to determine whether:  1) RA patients have antibodies to homocitrullinated fibrinogen (AHFA) and 2) ACPA and AHPA are cross-reactive.

Methods:

Serum was obtained from patients who met ACR criteria for RA, Psoriatic Arthritis or Systemic Lupus Erythematosus and were compared to healthy controls. It was tested against the following antigens: fibrinogen (fib), citfib, homocitrullinated fibrinogen (homocitfib), JED (a proprietary synthetic citrullinated peptide) and homocitrullinated JED (homoJED). Citrullination was done in vitro using peptidyl arginine deiminase enzyme (PAD2) [1]. Homocitrullination was done using potassium isocyanate. Both modifications were confirmed by mass spectrometry using ESI-MSMS and MASCOT server analysis. Shared Epitope (SE) binding was predicted by a computer algorithm [2]. ACPA was purified by affinity chromatography using JED. Antibodies to the above antigens and cyclic citrullinated peptide 2 (CCP2) were detected by ELISA. Inhibition assays using fib and homocitfib were conducted by ELISA.  

Results:

Mass spectrometry of modified fibrinogen revealed 55/79 (70%) of arginines were citrullinated and 89/103 (86%) of lysines were homocitrullinated. Approximately 25% of MHCII-binding peptides were both citrullinated and homocitrullinated. Five of these peptides were predicted to bind to the SE. The majority of RA patients were anti-CCP2 positive (89%) and 50% expressed AHFA. None of the normal controls and <5% of PsA and SLE were AHFA positive. All AHFA positive patients were also anti-CCP2 positive. Reactivity to homocitrullinated sites on fibrinogen was confirmed by inhibition assays. Affinity purified ACPA using a citrullinated peptide (JED) had reactivity to JED, anti-CCP2, as well as the homocitrullinated peptides, homoJED and homocitfib.

Conclusion:

Antibodies to homocitrullinated peptides/proteins are specific for RA. These antibodies bind citrullinated and homocitrullinated antigens, suggesting cross-reactivity and possible pathogenicity. 

[1] Mydel et al. 2010. J Immunol 184(12):6882.

[2] Hammer et al. 1994. J Exp Med 180(6): 2353.


Disclosure:

M. Scinocca,
None;

R. Joseph,
None;

D. A. Bell,
None;

E. Cairns,
None;

L. J. Barra,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/antibodies-to-citrulline-from-rheumatoid-arthritis-patients-also-bind-homocitrulline/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology